ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y(12)

FEBS Lett. 2002 Feb 27;513(2-3):179-83. doi: 10.1016/s0014-5793(02)02255-x.

Abstract

In this study we characterized the subtypes of nucleotide P2Y receptors that respond to ADP in glioma C6 cells. Direct visualization of phosphatidylinositol 4,5-bisphosphate at the cell surface revealed that extracellular ADP activates phospholipase C (PLC). Knock-down of P2Y(1) receptor with antisense oligonucleotide, as well as treatment with MRS2179 and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (P2Y(1) antagonists), attenuates receptor-mediated PLC activity. Adenylyl cyclase inhibition by ADP remains unchanged under these conditions. Reverse transcription-PCR analysis showed that P2Y(12) receptor is expressed in C6 cells. We therefore conclude that, in glioma C6 cells, two P2Y receptor subtypes are present: P2Y(1), coupled to PLC, and P2Y(12), negatively coupled to adenylyl cyclase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Diphosphate / metabolism
  • Adenylyl Cyclase Inhibitors
  • Adenylyl Cyclases / metabolism*
  • Animals
  • Enzyme Activation
  • Glioma / enzymology*
  • Membrane Proteins*
  • Rats
  • Receptors, Purinergic P2 / metabolism*
  • Receptors, Purinergic P2Y1
  • Receptors, Purinergic P2Y12
  • Tumor Cells, Cultured
  • Type C Phospholipases / metabolism*

Substances

  • Adenylyl Cyclase Inhibitors
  • Membrane Proteins
  • P2ry1 protein, rat
  • P2ry12 protein, rat
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2Y1
  • Receptors, Purinergic P2Y12
  • Adenosine Diphosphate
  • Type C Phospholipases
  • Adenylyl Cyclases